Analysts at Canaccord Adams think that Protalix BioTherapeutics (NYSE: PLX) PDUFA for Protalix's taliglucerase, largely expected for February ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE